SNY Sanofi SA
- Price as of: Sep 30, 12:33 PM EDT
- Drug manufacturers - major
SNY Stock Dividend DataAdd SNY to Watchlist
Looking to buy or sell SNY?
SNY Upcoming Dividend Payouts
Capture Sanofi SA Dividend with Much Less Risk
SNY Daily Snapshot
- Quote Time:
- Sep 30, 12:33 PM
- Today's Volume:
- Open Price:
- Day's Range:
- $37.67 - $38.22
- Previous Close:
- 52 Week Low / High:
- $37.41 - $51.88
- Percent Off 52 Week High:
SNY Dividend Growth History
SNY Dividend History
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
SNY Company Profile
Sanofi (SNY), formerly known as Sanofi-Aventis, engages in the research, development, manufacture, and marketing of healthcare products worldwide. It offers products in various therapeutic fields, including cardiovascular, thrombosis, oncology, metabolic disorders, central nervous system, and internal medicine and vaccines. The company was founded in 1970 and is headquartered in Paris, France.
Sanofi SA News
April 22, 2015
Before Wednesday’s opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the most important analyst commentary for investors.
October 15, 2015
A number of big-name dividend stocks were subject to analyst moves before the opening bell today. We highlight the most important changes, along with analyst commentary below.
December 15, 2015
One of the biggest misconceptions in investing is that domestic markets are somehow safer and better than investing abroad. For whatever reason, many of us believe that owning stocks and bonds in the U.S. is the best way to go. As a result, this...
Nov 26, 2014Excuse the cheesy title, but it's true. For investors looking to put capital to work in today's environment, the domestic equity landscape may...
Jul 31, 2014Here at Dividend.com, we constantly emphasize the importance of strong fundamentals when it comes to making any investment decision. However, with...
Today's Pre-Market Earnings: Archer Daniels Midland Company, Valero Energy Corporation, Coach Inc, More (ADM, VLO, COH, More)Apr 29, 2014Before the opening bell on Tuesday, a number of big name, dividend paying companies announced their quarterly earnings. Below, we look at these...
Sanofi Reports Positive Test Results for New Flu Treatment (SNY)Aug 26, 2013Early on Monday, pharmaceutical company Sanofi SA (SNY) announced that it saw topline results in its large-scale, multi-center efficacy trial of Fluzone High-Dose Influenza Virus Vaccine in people 65 years of age and older, relative to the standard dose of Fluzone in preventing the flu. In other words, the tests showed that Fluzone High-Dose does a better job at preventing the flu among older people than a standard dose of Fluzone. Sanofi Pasteur, the company's vaccines division, expects to submit the full clinical study to the FDA for review by early 2014. "We are pleased that this study demonstrates the superior relative efficacy of Fluzone High-Dose vaccine compared to Fluzone vaccine in preventing influenza in older adults," said David P. Greenberg, M.D., Vice President, U.S. Scientific and Medical Affairs, Sanofi Pasteur. "This efficacy trial complements the previous evidence of superior immune responses for Fluzone High-Dose vaccine compared to Fluzone vaccine and reaffirms the Phase III safety data in this population that were the basis for FDA licensure of Fluzone High-Dose vaccine in 2009." Sanofi SA shares were up 54 cents, or 1.07%, during pre-market trading on Monday. The stock is up 6.59% year-to-date. The Bottom Line Shares of Sanofi (SNY) offer a dividend yield of 3.68% based on Friday's closing price of $50.50 and the company's annualized dividend payout of $1.86 per share. Sanofi SA (SNY) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Feb 7, 2013These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Advance Auto Parts...
Sanofi-Aventis Makes Hostile Bid for Genzyme (SNY)Oct 4, 2010French pharmaceutical giant Sanofi-Aventis SA (SNY) on Monday announced it has made a hostile takeover bid for biotech company Genzyme Corp. (GENZ). Sanofi's tender offer, which was made directly to shareholders of Genzyme, is for $69 per common share. The total value of such a transaction is around $18.5 billion. Genzyme has until December 10, 2010, to either accept or decline the offer, as it will expire on that date. The offer represents a 38% premium Genzyme's July 1 closing price, but is actually lower than GENZ's Friday closing price of $70.88. Genzyme's shares have rocketed higher in recent months, since the initial takeover rumors began. Sanofi-Aventis shares were mostly flat in premarket trading Monday. The Bottom Line We had removed shares of SNY from our recommended list back on Apr.27, when the stock was trading at $36.10. The company has a 4.29% dividend yield, based on Friday's closing stock price of $33.12 The stock has technical support in the $30 price area. If the shares can firm up, we see overhead resistance around the $36-$38 price levels. We would remain on the sidelines for now. Sanofi-Aventis SA (SNY) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.3 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Sanofi-Aventis Offers $18.5 Billion for Genzyme (SNY, GENZ)Aug 30, 2010French pharma giant Sanofi-Aventis SA (SNY) on Monday officially announced an $18.5 billion takeover bid for biotech company Genzyme Corporation (GENZ). Sanofi said it first made the offer on July 29, which Genzyme quickly refused as undervaluing the company. Now, Sanofi is putting the pressure on Genzyme to head to the negotiating table by going public with the bid. "We feel we are left with no choice but to take our compelling proposal directly to your shareholders by making its terms public," said Sanofi CEO Christopher Viehbacher in a letter to Genzyme management. In response, Genzyme CEO Henri Termeer said "[the offer] provides no new information and no improvement in price, and therefore fails to establish a basis for engagement by the Genzyme board." Thus far, Sanofi claims that Genzyme has been "unwilling even to meet" to discuss a possible deal. The $69 per-share cash offer represented a 38% premium over GENZ's July 1 closing price. Sanofi-Aventis shares rose 16 cents, or +0.6%, in premarket trading Monday. The Bottom Line We had removed shares of SNY from our recommended list back on Apr.27, when the stock was trading at $36.10. The company has a 4.91% dividend yield, based on last night's closing stock price of $28.92. The stock has technical support in the $26 price area. If the shares can firm up, we see overhead resistance around the $32 price level. We would remain on the sidelines for now. Sanofi-Aventis SA (SNY) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.3 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story